Organization: Merck & Co Inc

Merck joins SGC, contributes $7.5 million

Merck & Co Inc is contributing $7.5 million to the Structural Genomics Consortium (SGC) as its newest corporate member. Merck’s decision to join the SGC was prompted by the organization’s status as a public-private partnership and its pioneering efforts to use open source intellectual property for moving technologies and medications into proprietary drug discovery programs.…

Merck joins SGC, contributes $7.5 million

Merck & Co Inc is contributing $7.5 million to the Structural Genomics Consortium (SGC) as its newest corporate member. Merck’s decision to join the SGC was prompted by the organization’s status as a public-private partnership and its pioneering efforts to use open source intellectual property for moving technologies and medications into proprietary drug discovery programs.…

Ambrilia inks major licensing deal with Merck

Montreal’s Ambrilia Biopharma Inc has entered a licensing agreement with Merck & Co Inc for worldwide rights to its HIV/AIDS protease inhibitor program. The deal will see Ambrilia receive US$17 million in an upfront licensing fee with payments of up to $215 million if it completes specified development, clinical, regulatory and sales milestones, as well…

Neuromed strikes major R&D deal with Merck

Neuromed Pharmaceuticals Ltd has signed an R&D collaboration and licencing agreement with Merck & Co Inc worth up to US$475 million if the Vancouver-based firm is successful in developing a new generation of pain killers and reaches milestones for four indications of its NMED-160 compound for pain treatment. The deal closely follows Neuromed’s completion of…